Gastric Cancer – Bemarituzumab Plus Chemo Improves Outcomes
Gastric cancer - Adding Bemarituzumab to chemo improves the results

Gastric Cancer – Bemarituzumab Plus Chemo Improves Outcomes

Background Gastric cancer has a new target to attack: FGFR2b. Anew drug, “Bemarituzumab”, targets FGFR2b. When Bemarituzumab was given with chemotherapy, the combination postponed the time until the disease recurred,…

Continue Reading Gastric Cancer – Bemarituzumab Plus Chemo Improves Outcomes